in samples from patients with CFA, 3 with the respiratory tract proposed as a possible resBackground -Cryptogenic fibrosing alveolitis (CFA) is a well defined clinical ervoir for EBV by others. 4 However, there have been few attempts to localise the EBV genome entity of unknown aetiology. An association between CFA and the presence in cells and there was a poor correlation between the titres of serum EBV antibodies and of protein indicating Epstein-Barr virus (EBV) replication within epithelial cells whether cells from patients were positive or negative for EBV DNA. Recently, evidence of of the respiratory tract has recently been suggested, leading to speculation for a role EBV replication within pulmonary epithelial cells in patients with CFA was suggested using for EBV in the pathogenesis of CFA. Methods -Lung tissue was obtained from immunochemistry, 5 although the study did not confirm the presence of EBV by examining patients in three groups: those with cryptogenic fibrosing alveolitis, either lone samples for the presence of DNA or RNA specific for EBV. In this study we sought to or associated with systemic sclerosis; patients with other pulmonary disorders; confirm previous observations which have implicated EBV in the pathogenesis of CFA by and patients with normal lung. Paraffin blocks were stained using three antibodies examining lung tissues from patients with CFA and comparing these with tissue from patients raised against well defined EBV antigens. In addition, EBER-1 and EBER-2 anti-with other pulmonary disorders and tissue from normal lung. Three well characterised antisense nucleotide probes were used in an attempt to identify EBV RNA. DNA was bodies raised against EBV were used to identify protein expression and polymerase chain realso extracted from the tissue sections and evaluated for evidence of EBV DNA using action (PCR) and in situ hybridisation were used to identify EBV DNA and RNA, rethe polymerase chain reaction. Results -Immunohistochemistry showed spectively. Brompton Hospital by one clinician (RdB).
in this study were a mixture of monoclonal anti-reduce non-specific interaction between DNA probes and tissue. Slides were washed in PBS, EBV LMP-1 antibodies (CS1-4), 6 monoclonal anti-EBV BZLF-1 protein, 7 and monoclonal dehydrated, air dried, and used for hybridisation on the same day or stored at −20°C. anti-EBV viral capsid antigen (VCA) (Chemicon International Inc, Temecula, California, For EBV RNA the following three EBER antisense oligonucleotide sequences were used USA). The antibodies were diluted in 1:20 rabbit serum in PBS. The sections were as a probe: (1) 5′-AAAACATGCGGACC-ACCAGC-3′ (6795-6776, EBER-1), (2) 5′-incubated with the optimal dilution of the primary antibodies (1:100 for CS1-4, 1:2000 for TCCTGACTTGCAAATGCTCT-3′ (7080-7061, EBER-2), and (3) 5′-CGGACAAG-BZ-1, and 1:1600 for VCA antibody) overnight in a humidifying chamber at 4°C. The sections and were deduced from the published EBERwere washed with PBS and incubated with biotinylated rabbit anti-mouse (Dako Ltd) for 1 and EBER-2 sequences.
9 These probes have previously been used successfully for the de-30 minutes, washed, and then incubated with avidin biotin peroxidase complex (Dako Ltd), termination of EBER by in situ hybridisation or PCR. 10 11 The three oligonucleotides were washed for 15 minutes, and visualised with 3, 3′-diamino benzidine (DAB) substrate (Dako 3′-end labelled with deoxyadenosine 5′-thiotriphosphate ( -35 S). Hybridisation was perLtd). The sections were counterstained with Mayer's haematoxylin solution (Sigma Diag-formed overnight at room temperature. After incubation the sections were washed, air dried, nostics, St Louis, USA) for one minute. After colour development, slides were examined for and dipped in Ilford K5 nuclear track emulsion.
After exposure periods of about two weeks the positive staining and scored for intensity of staining in coded fashion by one observer sections were developed and counterstained in Mayer's haematoxylin and mounted. (AGN) on a semiquantitative scale of −, +/−, +, ++, +++, with −=no staining, EBV positive lymphoma and EBV positive cultured cells were used as positive controls +=definitive staining, ++=prominent staining, and +++=strong staining. In control and one section from both the control and each specimen were treated before hybridisation sections (EBV positive lymphoma and EBV positive cultured cells) specificity was dem-with 20 g/ml of ribonuclease A (Sigma, Poole, UK) and 80 units/ml of ribonuclease T1 in onstrated by either omission of the primary antibody step or treatment of sections with PBS at 37°C for 30 minutes in order to confirm specificity. purified normal rabbit serum (Dako Ltd).
  
   DNA was extracted from paraffin-embedded The procedure for in situ hybridisation was modified from previously described methods. 8 samples as previously described.
12 PCR amplification of the BamHIW repeat of EBV was Briefly, 3-4 m sections were cut from lung biopsy specimens embedded in paraffin and carried out using the primers described by
Brocksmith et al and the products were analysed were mounted on poly--lysine coated slides. Tissue sections were dewaxed and rehydrated on 3% agarose gels.
13 All samples were amplified in duplicate. DNA extracted from a through an alcohol series to PBS, treated with proteinase K followed by acetylation with 0.1% paraffin section of a B cell lymphoma with Southern blot proven EBV was used as a posiacetic anhydride in 0.1 M triethanolamine to group.bmj.com on May 2, 2017 -Published by http://thorax.bmj.com/ Downloaded from different antibodies, not only in distribution but also in intensity. Also, when in situ hybridisation for EBER RNA was used, none of the samples from any of the patients was positive in any area showing positivity by immunohistochemistry. However, EBV positive lymphoma and EBV positive cultured cells showed presence of EBER RNA. Three cases, two of CFA and one of a foregut cyst removed from the mediastinum of a patient with a squamous cell carcinoma, gave a positive result for EBV DNA using PCR amplification on a single occasion. Duplicate specimens in these three cases and a further amplification in two were negative.
Discussion
The present study was conducted to evaluate 
CFA. The hypothesis that EBV infection was antibody to CS1-4. Haematoxylin was used as a counterstain (original magnification ×400).
associated with any form of interstitial lung disease was first suggested by Liebow and Carrington in relation to lymphocytic interstitial pneumonia.
14 Their hypothesis was supported by work using in situ hybridisation which showed the presence of EBV in type 2 epithelial cells in these patients. Interestingly, this work by Barbera et al failed to show evidence of EBV DNA in patients with fibrosing alveolitis whom they used as controls.
15
Vergnon et al 3 have shown a high prevalence of serum antibodies to EBV and IgA against the viral capsid antigen (VCA), suggesting that EBV may play a part in the aetiology of CFA, but citing the caveat that raised levels of IgG and IgA may be related to non-specific depression of cell mediated immunity. 3 In another study of 61 necropsy cases with secondary diffuse interstitial pneumonia, EBV was detected in seven patients using immunohistochemistry. However, no viral inclusions were observed.
2 In another study tuboreticular ease and viral pneumonia, although this study
Haematoxylin was used as a counterstain (original magnification ×400). In this case staining was not present with the other two antibodies at this site.
failed to identify such structures in 30 patients with CFA. 16 Most recently, Egan et al have suggested that EBV replicates in epithelial cells of patients with CFA after positive findings in tive control with each experiment. We used approximately 25 ng of this DNA and 14 out of 20 patients.
5 Keeping in view the discrepancy between the studies of Barbera et 50-100 ng of test sample DNA, and 40 cycles of PCR were used.
al and Egan et al, it was emphasised by Hogg in 1995 that experiments that examine lung tissue for viral DNA, RNA and proteins will be needed to clarify why the EBV replicative Results The results are summarised in table 1. proteins might be present when the internal repeat DNA is not.
17
Immunohistochemical analysis yielded localised positive staining, not only in cases of In the present study we set out to confirm these findings by immunohistochemistry, and CFA (fig 1) but also in normal lung (fig 2) and lung affected by other disease processes. also to look for EBV RNA and EBV DNA using in situ hybridisation and gene amplification, Staining was present in respiratory type epithelium, alveolar epithelium and, in two cases respectively, as support for the concept that EBV is present at disease sites. We investigated (nos 19 and 24), seromucinous glands where the staining was at its most intense (fig 3) . Serial samples from 27 patients and controls, including 12 cases of CFA. Some staining was sections were used to assess the distribution of the staining with all three antibodies within the found in cases of CFA using an antibody raised against VCA which was used in the study by tissue. A few cases showed positive staining at the same foci on adjacent sections, but most Egan et al, 5 and also with antibodies BZLF-1 and CS1-4. However, staining was also present showed wide variability of staining with the group.bmj.com on May 2, 2017 -Published by http://thorax.bmj.com/ Downloaded from such as within an occasional cell, possibly a lymphocyte. Unfortunately, because the tissues are archival, there was no access to blood to look for serological evidence of EBV infection but the normal incidence of infection in the population would lead us to expect that at least 90% of the cases would be seropositive for EBV. Furthermore, the absence of positivity in these lung samples using in situ hybridisation demonstrates the difficulties associated with relying on a single reagent to test for the presence of EBV in tissue samples of this type. If EBV was replicating in its lytic cycle, coincident expression of BZLF-1 and VCA would be expected, and if it was latent the EBER and LMP1 (CS1-4) probes should have detected this type of infection. Whatever the type of EBV infection, the viral DNA should have been detectable. In conclusion, the lack of consistent viral antigen expression and general failure genic fibrosing alveolitis does not appear to be associated with EBV infection.
